...
首页> 外文期刊>Green chemistry >En route to full implementation: driving the green chemistry agenda in the pharmaceutical industryt
【24h】

En route to full implementation: driving the green chemistry agenda in the pharmaceutical industryt

机译:全面实施的道路:推动制药行业的绿色化学议程

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

What is the relationship between the Green Chemistry initiative and the pharmaceutical industry? The intention is to shed some light on this issue by providing an historical overview spanning a period of about 20 years - from the start of the movement towards greener processes and manufacture in the early 1990s until today where greenness and sustainability are widely embraced throughout society. To understand and appreciate the approach to the green paradigm from a pharmaceutical business point of view, it is essential to paint the broader picture explaining the landscape in which this industry operates and its particular challenges. Looking at the special features that apply to chemical production of drug molecules for commercial use-In relative terms a low volume undertatcing (from kg scale through to 10s or sometimes 100s of tons per annum) - the situation is vastly different compared to conventional bulk manufacture (for instance of commodity chemicals). After an initial lag phase, the drug industry has now caught up and is very eager to fully adopt green principles and to gather evidence on how it is performing. As an example, it is a well documented fact that more than half the mass constituting a process stream in the chemical manufacture of active pharmaceutical ingredients (APIs) stems from the solvent(s) utilized; 80-90% if water is included. In a multi-step synthesis on an average composed of 8-10 discrete chemical transformations which typically runs at a process mass intensity (PMI) factor of 100-200 kg kg~(-1) API, about 50-100 kg can be referred purely to the contribution from solvents; hence, the potential for improvements is huge. Thus, leaving the historic priorities behind in favor of drivers for change such as external pressure, goodwill, legislation, and company policies is a good strategy to ensure a rapid movement into a greener future, albeit without ignoring the existence of blockers that mainly relate to insufficient scientific and technological capabilities. From a chemical process point of view, there are several reasons to have an optimistic view about the prospects of a flourishing green agenda going forward as shown in a number of recent case studies.
机译:绿色化学倡议与制药行业之间有什么关系?通过从20世纪90年代初期开始向更绿色的过程和制造运动发展到今天的绿色和可持续性被整个社会广泛采用的大约20年的历史回顾,目的旨在阐明这一问题。为了从制药企业的角度理解和理解绿色范式的方法,必须画出更广阔的图景来解释该行业的经营状况及其特殊挑战。着眼于适用于商业用途的药物分子化学生产的特殊功能-相对而言,产量低(从公斤级到每年10吨或有时是100吨)-与传统的批量生产相比,情况大不相同(例如商品化学品)。在最初的滞后阶段之后,制药业现在已经赶上并非常渴望完全采用绿色原则并收集有关其表现的证据。例如,有充分的事实证明,在化学生产活性药物成分(API)的过程中,构成过程流的质量有一半以上来自所使用的溶剂。如果包括水,则为80-90%。在平均由8-10个离散化学转化组成的平均多步合成中,通常以100-200 kg kg〜(-1)API的过程质量强度(PMI)因子运行,可以引用约50-100 kg纯粹是由于溶剂的贡献;因此,改进的潜力是巨大的。因此,抛弃历史上的优先事项,而支持诸如外部压力,商誉,立法和公司政策之类的变革驱动力,这是确保迅速迈向绿色未来的好策略,尽管它不忽略主要存在与之相关的阻碍因素科学技术能力不足。从化学过程的角度来看,有许多理由对不断发展的绿色议程的前景持乐观态度,如最近的一些案例研究所示。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号